Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ProLung Inc
LUNG | US
1.52
USD-0.09
-5.59%
LUNG | US
About ProLung Inc
Sector
Healthcare
Industry
Medical Devices
Earnings date
30/06/2024
As of date
03/06/2026
Close
1.52
Open
1.58
High
1.61
Low
1.49
Pulmonx Corporation a commercial-stage medical technology company provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction fissure completeness and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States Europe the Middle East Africa the Asia-Pacific and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. The company was incorporated in 1995 and is headquartered in Redwood City California.
View LessLUNG | US
Risk
72.9
Sharpe
-0.58
Luna's Score
46/100
Recommendation
Hold
Luna says (LUNG | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
What's not Working
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
97.6%1 month
72.9%3 months
90.1%6 months
81.6%Returns
Fundamental Ratios
PE
-
Fwd. PE
28.33
Price to book
2.52
Debt to equity
0.56
Debt to assets
0.33
Ent. to EBITDA
-5.62
Ent. to rev.
2.56
PEG
-
Other Fundamentals
EBITDA
-56.93M
MarketCap
59.51M
MarketCap(USD)
59.51M
Div. yield
-
Op. margin
-75.17
Erngs. growth
-
Rev. growth
20.90
Ret. on equity
-49.22
Short ratio
5.98
Short perc.
6.08
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.38
Range1M
0.51
Range3M
1.03
Volumes: Market Activity
Rel. volume
0.89
Price X volume
619.79K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -5.62 | - | Cheaper |
| Ent. to Revenue | 2.56 | - | Cheaper |
| PE Ratio | - | 30.41 | - |
| Price to Book | 2.52 | 6.21 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 90.12 | - | Riskier |
| Debt to Equity | 0.56 | -145.53 | Expensive |
| Debt to Assets | 0.33 | 0.35 | Par |
| Market Cap | 59.51M | - | Emerging |
